3-cyano-2,4-dioxo-tetrahydroquinoline | 1356125-45-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-cyano-2,4-dioxo-tetrahydroquinoline
• 英文别名: 2,4-dioxo-1H-quinoline-3-carbonitrile
• CAS: 1356125-45-5
• 化学式: C₁₀H₆N₂O₂
• 分子量: 186.17
• InChiKey: CMUGRNYKIQBBBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-cyano-2,4-dioxo-tetrahydroquinoline 在 五氯化磷 、 三氯氧磷 作用下， 反应 4.0h， 以70%的产率得到2,4-二氯喹啉-3-甲腈
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of New Diaminoquinazolines as β-Catenin/Tcf4 Pathway Inhibitors

  摘要：

  More than 50 new diaminoquinazoline derivatives have been synthesized and evaluated in a colon carcinoma cell growth inhibition assay using HCT116 and SW480 cells. Twenty compounds with good cell growth inhibitory activities (<4 mu M) were tested as inhibitors of the beta-catenin/T cell transcription factor 4 (Tcf4) signaling pathway using a HCT116 cell-based luciferase reporter assay. Results from the biological activities as well as the comparative molecular field analysis (CoMFA) of the properties of the molecules yielded a preliminary structure-activity relationship (SAR). Three potent compounds, 74, 78, and 86, showed IC50 values <1 mu M for growth inhibition of HCT116 cells and similar to 1 mu M for SW480 cells, as well as IC50 values of 1.5-2.5 mu M for HCT116 cells with the luciferase reporter assay.

  DOI：

  10.1021/jm201494a
• 作为产物：
  描述：

  3-苯胺基-2-氰基-3-氧代丙酸乙酯 以 邻二氯苯 为溶剂， 反应 6.0h， 以61%的产率得到3-cyano-2,4-dioxo-tetrahydroquinoline
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of New Diaminoquinazolines as β-Catenin/Tcf4 Pathway Inhibitors

  摘要：

  More than 50 new diaminoquinazoline derivatives have been synthesized and evaluated in a colon carcinoma cell growth inhibition assay using HCT116 and SW480 cells. Twenty compounds with good cell growth inhibitory activities (<4 mu M) were tested as inhibitors of the beta-catenin/T cell transcription factor 4 (Tcf4) signaling pathway using a HCT116 cell-based luciferase reporter assay. Results from the biological activities as well as the comparative molecular field analysis (CoMFA) of the properties of the molecules yielded a preliminary structure-activity relationship (SAR). Three potent compounds, 74, 78, and 86, showed IC50 values <1 mu M for growth inhibition of HCT116 cells and similar to 1 mu M for SW480 cells, as well as IC50 values of 1.5-2.5 mu M for HCT116 cells with the luciferase reporter assay.

  DOI：

  10.1021/jm201494a

文献信息

• [EN] SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS SUBSTITUÉS DE 2, 4-DIAMINO-QUINOLÉINE POUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：GENOSCIENCE PHARMA

  公开号：WO2017191599A1

  公开（公告）日：2017-11-09

  This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non- neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non- neoplastic disorders such as rheumatoid arthritis.

  本申请披露了根据通用式（I）定义的化合物，其中所有变量如本文所述，这些化合物对各种癌细胞系表现出强烈的抑制作用。本文披露的化合物对于治疗增生性疾病非常有用，包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎。还披露了含有通用式（I）化合物和至少一种载体、稀释剂或赋形剂以及可选的一种或多种其他治疗活性剂的药物组合物。本申请还披露了治疗增生性疾病的方法，包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎的方法。
• [EN] OXY-CYANOQUINOLINONE PDE9 INHIBITORS<br/>[FR] OXY-CYANOQUINOLINONE UTILISÉE EN TANT QU'INHIBITEUR DE PDE9
  申请人：MERCK SHARP & DOHME

  公开号：WO2017019726A1

  公开（公告）日：2017-02-02

  The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及氧氰喹啉酮化合物，可能作为治疗与磷酸二酯酶9（PDE9）相关的中枢神经系统障碍的治疗剂。本发明还涉及利用这些化合物治疗神经学和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底节功能障碍相关的疾病。
• Pyrazoloquinolone Derivative And Use Thereof
  申请人：Fukumoto Shojl

  公开号：US20070281963A1

  公开（公告）日：2007-12-06

  The present invention provides a pyarzoloquinolone derivative having kinase inhibitory activity. The derivative is represented by the formula: wherein R 1 is an aryl group which may be substituted, or an aromatic heterocyclic group which may be substituted; R 2 is a hydrogen atom, an amino group which may be substituted, a hydroxy group which may be substituted, or a thiol group which may be substituted; R 3 , R 4 , R 5 and R 6 , which may be identical or different, are each (1) a hydrogen atom, (2) a nitro group, (3) a cyano group, (4) a halogen atom, (5) a hydrocarbon group which may be substituted, (6) an amino group which may be substituted, (7) a hydroxy group which may be substituted, or (8) a thiol group which may be substituted; and R 3 and R 4 , R 4 and R 5 , and R 5 and R 6 may respectively form a ring together with the adjacent carbon atom, or salt thereof.

  本发明提供了一种具有激酶抑制活性的吡唑喹啉衍生物。该衍生物由以下公式表示：其中，R1是可以被取代的芳基或可以被取代的芳香杂环基；R2是氢原子，可以被取代的氨基，可以被取代的羟基或可以被取代的硫醇基；R3、R4、R5和R6可以相同也可以不同，分别是（1）氢原子，（2）硝基，（3）氰基，（4）卤原子，（5）可以被取代的碳氢基，（6）可以被取代的氨基，（7）可以被取代的羟基或（8）可以被取代的硫醇基；R3和R4，R4和R5，以及R5和R6可以分别与相邻的碳原子形成环，或其盐。
• Oxy-cyanoquinolinone PDE9 inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10370337B2

  公开（公告）日：2019-08-06

  The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及氧基氰基喹啉酮化合物，该化合物可作为治疗剂用于治疗与磷酸二酯酶9（PDE9）相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病或亨廷顿氏病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
  申请人：GENOSCIENCE PHARMA

  公开号：US10577362B2

  公开（公告）日：2020-03-03

  This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.

  本申请公开了符合通式 I 的化合物：其中所有变量的定义如本文所述，这些化合物对各种癌细胞系具有很强的抑制作用。本文公开的化合物可用于治疗增殖性疾病，包括肿瘤性疾病（如癌症）和非肿瘤性疾病（如类风湿性关节炎）。本申请还公开了含有式 I 化合物和至少一种载体、稀释剂或赋形剂的药物组合物，以及一种或多种额外的治疗活性剂，包括抗癌剂。本申请还公开了治疗增殖性疾病的方法，包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎。